Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

2 Apr 2009 07:00

RNS Number : 9727P
ViaLogy PLC
02 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY TO RAISE UP TO £1.5 MILLION

LONDONApril 2, 2009 - ViaLogy PLC (LSE: VIY).  The Company today announces it is to offer investors who participated in ViaLogy's 2007 and 2008 funding rounds the opportunity to exercise their warrants at a reduced price.  It is proposed that the 27,500,000 warrants issued in October 2007 ("2009 Warrants") exercisable at 10 pence per Ordinary Share will be exercisable at 2.5 pence until noon on Thursday, 30 April 2009 (the "End Date") It is further proposed that the 45,000,000 warrants issued in October 2008 ("2010 Warrants") exercisable at 5 pence per Ordinary Share will be exercisable at 2 pence until the End Date In addition, for the 1,193,654 warrants held by George Rehm and Michael Kelly, both Directors, (exercisable at 4 pence per share) and a total of 2,500,000 warrants held by Dr Richard Dixey and Mark Tompkins (exercisable at 6 pence per share) will be reduced to 2 pence per share during the same period.

Full exercise of all outstanding 2009 Warrants and 2010 Warrants prior to the End Date, at the reduced subscription prices, would raise £1,587,500 (before expenses) for the Company. After the End Date, the original subscription prices relating to all such warrants will apply.

In accordance with the terms of their constitution, the proposed variation of the subscription prices applying to the 2009 Warrants and 2010 Warrants must be approved by, and is conditional upon the passing of, extraordinary resolutions to be proposed at meetings of the holders of such warrants. Accordingly, the Company has today convened meetings of the holders of the 2009 Warrants and the 2010 Warrants to be held on Monday, 20 April 2009.

The Company has also today entered into agreements with certain institutions and individuals ("Subscribers") who have undertaken to subscribe for such number of new Ordinary Shares ("Subscriber Shares") as has an aggregate subscription price of £1,587,500, less the aggregate amount of the proceeds of the exercise of warrants by warrant holders (the "Subscription").  The aggregate number of Ordinary Shares to be subscribed by such persons shall not, however, exceed 50,377,300 (representing approximately 10 per cent. of the Company's current issued share capital), which is the maximum number of Ordinary Shares the Directors are authorised to issue for cash, pursuant to resolutions passed at the Annual General Meeting of the Company held on 29 October 2008, other than pro rata to existing shareholders. The subscription price payable for the Subscriber Shares will be determined by the number of warrants which holders of the 2009 Warrants and 2010 Warrants elect to exercise, but shall be not less than 2 pence for the first 45 million Subscriber Shares and 2.5 pence for the remaining Subscriber Shares.

In consideration of the Subscribers agreeing to subscribe for the Subscriber Shares, and so guarantee that the amount of funds to be received by ViaLogy pursuant to the proposed fundraising, (before expenses) is not less than £1,034,432.50, the Company has agreed to pay to such Subscribers an aggregate fee of £79,375 being 5% of £1,587,500, which is the maximum amount to be raised by the Company, assuming full exercise of the 2009 Warrants and the 2010 Warrants. 

Application will be made for the Ordinary Shares issued upon the valid exercise of outstanding warrants and the Subscriber Shares to be admitted to trading on AIM.

"The board decided to re-price the warrants in conjunction with the Subscription for two main reasons," said ViaLogy chairman Terry Bond. "Firstly, shareholder dilution is minimised because the warrants are already accounted for in the Company's fully diluted financial position.  Secondly, ViaLogy needs additional funding for future on-going expenditure, including the opportunity to increase our financial participation in the successful well our QuantumRD technology has identified on the Galba Oil Prospect in south central Texas.  Atascosa Exploration LLC, who commissioned us to analyse the seismic data and advise on drilling locations, were so pleased with the results that they offered us very attractive terms to double ViaLogy's working interest in the first well production to 10%. The re-pricing of the warrants seemed a very elegant solution to our funding requirements whilst minimising any dilution effect."

Ends

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Nominated Advisor (Seymour Pierce)   Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 7628 5582 

About ViaLogy

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications.  ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential.  ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter.  This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications.  For more information, visit our website at www.ViaLogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDGGDSBUGGGCB
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.